Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
177 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape. Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections. Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cytomegalovirus (HHV-5) Infections Overview 9 Therapeutics Development 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11 Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12 Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 14 Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20 Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23 Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 25 Adicet Bio, Inc. 25 AIMM Therapeutics BV 26 Astellas Pharma Inc 27 Atara Biotherapeutics Inc 28 AvidBiotics Corp 29 Biotest AG 30 Chimerix Inc 31 China Biologic Products Inc 32 CyTuVax BV 33 Fate Therapeutics Inc 34 GlaxoSmithKline Plc 35 Hookipa Biotech AG 36 Kadmon Corp LLC 37 Laboratoires Thea SA 38 Merck & Co Inc 39 Microbiotix Inc 40 Mymetics Corp 41 Novartis AG 42 Pfizer Inc 43 Phoenix Biotechnology Inc 44 Savoy Pharmaceuticals, Inc. 45 Sigma-Tau SpA 46 Themis Bioscience GmbH 47 Trellis Bioscience Inc 48 Vakzine Projekt Management GmbH 49 VBI Vaccines Inc 50 Vical Inc 51 Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 AIC-387 - Drug Profile 62 AIC-476 - Drug Profile 63 AIC-813 - Drug Profile 64 AL-18 - Drug Profile 65 Antibody for Human Cytomegalovirus Infection - Drug Profile 66 ASP-0113 - Drug Profile 67 brincidofovir - Drug Profile 70 BT-084 - Drug Profile 84 Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 85 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 86 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 87 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 88 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 89 Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 90 Cellular Immunotherapy for Infectious Disease - Drug Profile 91 Cellular Immunotherapy for Infectious Diseases - Drug Profile 92 Cellular Immunotherapy for Viral Infections - Drug Profile 93 Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 94 Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 95 Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 96 Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 98 Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 99 CMX-669 - Drug Profile 100 CSJ-148 - Drug Profile 101 CyMVectin - Drug Profile 102 cytomegalovirus (virus like particle) vaccine - Drug Profile 104 Cytomegalovirus (virus like particle) vaccine - Drug Profile 105 Cytomegalovirus vaccine - Drug Profile 106 Cytomegalovirus vaccine - Drug Profile 107 Cytomegalovirus vaccine - Drug Profile 108 filociclovir - Drug Profile 109 ganciclovir - Drug Profile 111 Gene Therapy for Cytomegalovirus Infections - Drug Profile 112 HB-101 - Drug Profile 113 letermovir - Drug Profile 114 maribavir - Drug Profile 117 MBX-2168 - Drug Profile 120 Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 121 Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 122 Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 123 Pentamer - Drug Profile 124 Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 125 PepVax - Drug Profile 126 ProTmune - Drug Profile 128 PTX-3 - Drug Profile 130 RBT-301 - Drug Profile 131 Recombinant Peptide for Infectious Diseases - Drug Profile 132 Recombinant Protein for CMV - Drug Profile 133 RKP-00156 - Drug Profile 134 Small Molecule for Cytomegalovirus - Drug Profile 135 Small Molecules for CMV Infections - Drug Profile 136 Small Molecules for CMV infections and Cancer - Drug Profile 137 Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 138 Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 139 Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 140 Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 141 Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 142 Triplex - Drug Profile 143 TRL-345 - Drug Profile 145 V-160 - Drug Profile 146 VBI-1501A - Drug Profile 147 Viralym-C - Drug Profile 149 Viroprev - Drug Profile 150 VPM-2001 - Drug Profile 151 Cytomegalovirus (HHV-5) Infections - Dormant Projects 152 Cytomegalovirus (HHV-5) Infections - Discontinued Products 157 Cytomegalovirus (HHV-5) Infections - Product Development Milestones 158 Featured News & Press Releases 158 Appendix 172 Methodology 172 Coverage 172 Secondary Research 172 Primary Research 172 Expert Panel Validation 172 Contact Us 172 Disclaimer 173
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016 14 Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Comparative Analysis by Unknown Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2016 27 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 28 Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H2 2016 29 Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2016 30 Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2016 31 Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2016 32 Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2016 33 Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2016 34 Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2016 35 Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2016 36 Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2016 37 Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2016 38 Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 39 Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2016 40 Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2016 41 Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H2 2016 42 Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2016 43 Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2016 44 Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H2 2016 45 Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2016 46 Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2016 47 Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2016 48 Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 49 Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2016 50 Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2016 51 Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2016 52 Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2016 53 Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2016 54 Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2016 55 Assessment by Monotherapy Products, H2 2016 56 Assessment by Combination Products, H2 2016 57 Number of Products by Stage and Target, H2 2016 59 Number of Products by Stage and Mechanism of Action, H2 2016 61 Number of Products by Stage and Route of Administration, H2 2016 63 Number of Products by Stage and Molecule Type, H2 2016 65 Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2016 156 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2016 157 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2016 158 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2016 159 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H2 2016 160 Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2016 161
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
